Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2002

View Archived Issues

Metformin XT is equivalent to immediate-release metformin in the treatment of type 2 diabetes

Use of LY-333531 in the treatment of diabetic complications

Eletriptan now available in Germany for migraine Rx

Nonapprovable letter issued for Casodex in early prostate cancer

AuraZyme awarded grant for drug delivery system development

Hydro Med obtains option to biodegradable polymer drug delivery system

BiDil to be evaluated in African American heart failure population

Alza and TransForm collaborate on drug optimization

Ixion receives grant for stem cell research in diabetes

FDA approves injectable Geodon for schizophrenia

ImmunoGen faces development setbacks with two TAP products

AMG-073 provides long-term benefits in primary hyperparathyroidism

Acyline suppresses testosterone in men for at least 19 days with minimal side effects

First-in-class SARM with strong anabolic effects characterized at ENDO 2002

AstraZeneca describes novel N-type calcium channel antagonists

Neurotrophin activity enhancers reported in Sankyo patent

Novel CNS-selective prostacyclin receptor ligands and their use

Comparative effects of SOM-230 and octreotide on GH and prolactin release

Angiogenesis inhibitors in early development at Sigma-Tau

New PARP inhibitors in GSK pipeline

FDA deems Vevesca nonapprovable

Lilly Icos continues to develop PDE5 inhibitors

Changes in Pennsaid marketing and distribution agreements

Radiolabeled CCR1 antagonists for use in diagnosis of AD

Preclinical and early clinical findings for TAK-013, a potent oral GnRH receptor antagonist

Nymox files NX-1207 IND in benign prostatic hyperplasia

ATL-962 cleared to enter phase IIb trial for obesity

Enrollment completed in phase II trial of tesmilifene combination therapy in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...